US12440499 — Topical composition
Method of Use · Assigned to MC2 Therapeutics Ltd · Expires 2039-03-18 · 13y remaining
What this patent protects
This patent protects a topical composition containing calcipotriol, betamethasone dipropionate, alpha-tocopherol, and butylated hydroxyanisole.
USPTO Abstract
The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.
Drugs covered by this patent
- Diprolene (BETAMETHASONE DIPROPIONATE) · Merck & Co.
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1408 |
— | Diprolene |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.